Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-04-12
2011-04-12
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S153000
Reexamination Certificate
active
07923457
ABSTRACT:
The invention relates to compounds represented by Formula (I):and to pharmaceutically acceptable salts or solvates of said compounds, wherein each of A, R3-8, X3, X5, m, and n are defined herein. The invention also relates to pharmaceutical compositions containing the compounds of Formula (I) and to methods of treating hyperproliferative disorders in a mammal by administering compounds of Formula (I).
REFERENCES:
patent: 3376195 (1968-04-01), Allais et al.
patent: 3755332 (1973-08-01), Wasley et al.
patent: 3936461 (1976-02-01), Schwender et al.
patent: 4421920 (1983-12-01), Baudouin et al.
patent: 4764454 (1988-08-01), Ichijima et al.
patent: 5792783 (1998-08-01), Tang et al.
patent: 5834504 (1998-11-01), Tang et al.
patent: 5883113 (1999-03-01), Tang et al.
patent: 5886020 (1999-03-01), Tang et al.
patent: 6071935 (2000-06-01), Lyssikatos
patent: 6143764 (2000-11-01), Kubo et al.
patent: 6225318 (2001-05-01), Sobolov-Jaynes et al.
patent: 6492383 (2002-12-01), Munchhof et al.
patent: 6797823 (2004-09-01), Kubo et al.
patent: 7381824 (2008-06-01), Hong et al.
patent: 2004/0053908 (2004-03-01), Funahashi et al.
patent: 2004/0132727 (2004-07-01), Sakai et al.
patent: 2004/0209905 (2004-10-01), Kubo et al.
patent: 2005/0049264 (2005-03-01), Miwa et al.
patent: 2005/0187236 (2005-08-01), Tsuruoka et al.
patent: 0326330 (1989-08-01), None
patent: 0602851 (1994-06-01), None
patent: 1086705 (2001-03-01), None
patent: 0 860 433 (2002-07-01), None
patent: 1251130 (2002-10-01), None
patent: 1 447 405 (2004-08-01), None
patent: 1 522 540 (2005-04-01), None
patent: 1548008 (2005-06-01), None
patent: 2.077.455 (1969-09-01), None
patent: 11-158149 (2002-09-01), None
patent: WO92/21660 (1992-12-01), None
patent: WO93/03030 (1993-02-01), None
patent: WO93/13097 (1993-07-01), None
patent: WO95/15758 (1995-06-01), None
patent: WO95/19970 (1995-07-01), None
patent: WO95/21613 (1995-08-01), None
patent: WO95/23141 (1995-08-01), None
patent: WO96/09294 (1996-03-01), None
patent: WO96/15118 (1996-05-01), None
patent: WO96/30347 (1996-10-01), None
patent: WO96/40142 (1996-12-01), None
patent: WO97/03069 (1997-01-01), None
patent: WO97/13771 (1997-04-01), None
patent: WO97/17329 (1997-05-01), None
patent: WO97/22596 (1997-06-01), None
patent: WO97/32856 (1997-09-01), None
patent: WO97/49688 (1997-12-01), None
patent: WO98/02437 (1998-01-01), None
patent: WO98/02438 (1998-01-01), None
patent: WO98/13350 (1998-04-01), None
patent: WO98/23613 (1998-06-01), None
patent: WO98/37079 (1998-08-01), None
patent: WO98/50356 (1998-11-01), None
patent: WO98/51344 (1998-11-01), None
patent: WO98/54093 (1998-12-01), None
patent: WO99/10349 (1999-03-01), None
patent: WO99/16755 (1999-04-01), None
patent: WO99/24440 (1999-05-01), None
patent: WO99/61422 (1999-12-01), None
patent: WO 00/18761 (2000-04-01), None
patent: WO 00/35919 (2000-06-01), None
patent: WO00/38665 (2000-07-01), None
patent: WO00/43366 (2000-07-01), None
patent: WO 00/47212 (2000-08-01), None
patent: WO 00/50405 (2000-08-01), None
patent: WO01/47890 (2001-07-01), None
patent: WO01/47931 (2001-07-01), None
patent: WO01/70268 (2001-09-01), None
patent: WO01/74296 (2001-10-01), None
patent: WO01/74360 (2001-10-01), None
patent: WO01/85796 (2001-11-01), None
patent: WO 02/12226 (2002-02-01), None
patent: WO02/30453 (2002-04-01), None
patent: WO 02/30925 (2002-04-01), None
patent: WO 02/32872 (2002-04-01), None
patent: WO02/41882 (2002-05-01), None
patent: WO02/064170 (2002-08-01), None
patent: WO03/006059 (2003-01-01), None
patent: WO 03/033472 (2003-04-01), None
patent: WO03/035047 (2003-05-01), None
patent: WO 03/074529 (2003-09-01), None
patent: WO 2004/018430 (2004-03-01), None
patent: WO 2004/020434 (2004-03-01), None
Abuzar, S., CA 105:42720, abstract only of Indian Journal of Chemistry, Section B; Organic Chem include Med Chem, Col. 24B(8), pp. 848-852, 1985.
Bussolino, F. et al. “Role of Soluble Mediators in Angiogenesis,”European Journal of Cancer, 1996, 32A:14, 2401-2412.
Chemical Abstract Accession No. 1981:407199. [Agrawal, V. et al., “Studies in Potential Filaraicides: Part XI. Synthesis of 2-(Dialkylaminomethyl)-4-Substituted Aminophenols aAs Amodiaquine Analogs,”Indian Journal of Chemistry, Section B, 1981, 95:1, 68682.].
Chemical Abstract Accession No. 1969:68193. [Hamana, et al., “4-Substituted Quinoline Derivatives,”Japan Tokkyo Koho, 1969, 70:15, 366.].
Chemical Abstract Accession No. 1994:217227. [Barlin, G. et al., “Potential Antimalarials. XVIII. Some Mono- and Di-Mannich Bases of 3-[7-Chloro(and Trifluoromethyl)Quinolin-4-ylamino]Phenol,”Australian Journal of Chemistry, 1993, 46:11, 1685-93.].
Deplanque, G. et al. “Anti-angiogenic Agents: Clinical Trial Design and Therapies in Development,”European Journal of Cancer, 2000, 36, 1713-1724.
Firsching, A. et al. “Antiproliferative and Angiostatic Activity of Suramin Analogues,”Cancer Research, 1995, 55, 4957-4961.
Folkman, A. et al. “New Perspectives in Clinical Oncology From Angiogenesis Research,”European Journal of Cancer, 1996, 32A:14, 2534-2539.
Gibson, K. H., CA 133:350152, abstract only of WO 2000/068200, Nov. 2000.
Gravatt, G. et al., “DNA-Directed Alkylating Agents. 4. 4-Anilinoquinoline-Based Minor Groove Directed Aniline Mustards,”Journal of Medicinal Chemistry, 1991, 34, 1552-1560.
Henniquin, L.F., CA 136:178717, abstract only of WO 2002/12226, Feb. 2002.
Kotva, R. et al. “Substances With Antineoplastic Activity. LIII.* N-{δ-(4-Pyrrolo[2,3-d]Pyrimidinylthio)Valeryl}Amino Acids and Analogous Derivatives of Di- and Triglycine,”Collection Czechoslov ChemicalCommun, 1973, 38:5, 1438-1444.
Rewcastle, G. et al. “Tyrosine Kinase Inhibitors. 5. Synthesis and Structure-Activity Relationships for 4-[(Phenylmethyl)Amino]- and 4-(Phenylamino)Quinazolines as Potent Adenosine 5]-Triphosphate Binding Site Inhibitors of the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor,”Journal of Medicinal Chemistry, 1995, 38, 3482-3487.
Spacey, G. et al. “Indolocarbazoles Potent and Selective Inhibitors of Platelet-Derived Growth Factor Receptor Autophosphorylation,”Biochemical Pharmacology, 1998, 55, 261-271.
Wang, F. et al., “A Convenience Set of Bidentate Pyridine Ligands for Combinatorial Synthesis,”Tetrahedron Letters 40, 1999, 4779-4782.
Aiello, L., et al., “Role of Vascular Endothelial Growth Factor in Diabetic Vascular Complications,”Kidney International, 2000, S-113-S119, vol. 58, No. 77.
Eckhardt, S., et al., “Development of Angiogenesis Inhibitors for Cancer Therapy,”Investigational New Drugs, 1997, 1-3, vol. 15.
Ferrara, N., et al., “The Biology of VEGF and its Receptors,”Nature Medicine, 2003, 669-676, vol. 9, No. 6.
Fong, T., et al., SU5416 is a Potent and Selective Inhibitor of the Vascular Endothelial Growth Factor Receptor (FLK-1/KDR) That Inhibits Tyrosine Kinase Catalysis, Tumor Vascularization, and Growth of Multiple Tumor Types,Cancer Research, 1999, 99-106, vol. 59.
O'Reilly, M., “The Preclinical Evaluation of Angiogenesis Inhibitors,”Investigational New Drugs, 1997, 5-13, vol. 15.
Parast, C., et al., “Characterization and Kinetic Mechanism of Catalytic Domain of Human Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase (VEGFR2 TK), A Key Enzyme in Angiogenesis,”Biochemistry, 1998, 16788-16801, vol. 37.
Wedge, S., et al., “ZD6474 Inhibits Vascular Endotheilial Growth Factor Signaling Angiogenesis, and Tumor Growth Following Oral Administration,”Cancer Research, 2002, 4645-4655, vol. 62.
Hong Yufeng
Kania Robert Steven
Agouron Pharmaceuticals , Inc.
Seaman D. Margaret
Tidwell Jeffrey H.
LandOfFree
Quinoline derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinoline derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinoline derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2690751